These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24703530)

  • 21. Colorectal cancer: to stack or sequence therapy?
    Azvolinsky A
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957442
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 24. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
    Larsen FO; Markussen A; Nielsen D; Colville-Ebeling B; Riis LB; Jensen BV
    Oncology; 2017; 93(3):191-196. PubMed ID: 28531891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
    Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
    J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence?
    Norguet E; Dahan L; Gaudart J; Gasmi M; Ouafik L; Seitz JF
    Dig Liver Dis; 2011 Nov; 43(11):917-9. PubMed ID: 21763224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial.
    Ooki A; Ando M; Sakamoto J; Sato A; Fujii H; Yamaguchi K
    Jpn J Clin Oncol; 2014 Apr; 44(4):383-7. PubMed ID: 24558128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada.
    Jerzak KJ; Berry S; Ko YJ; Earle C; Chan KK
    Int J Cancer; 2017 May; 140(9):2162-2167. PubMed ID: 28220486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cetuximab for metastatic colorectal cancer.
    Garattini S; Torri V; Floriani I
    N Engl J Med; 2009 Jul; 361(1):96; author reply 96-7. PubMed ID: 19579281
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of metastatic colon cancer: "the times they are A-changing".
    Kemeny NE
    J Clin Oncol; 2013 Jun; 31(16):1913-6. PubMed ID: 23630214
    [No Abstract]   [Full Text] [Related]  

  • 31. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Frati L; Codacci-Pisanelli G
    N Engl J Med; 2009 May; 360(20):2134-5; author reply 2135-6. PubMed ID: 19445031
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.
    Cheng L; Ren W; Xie L; Li M; Liu J; Hu J; Liu BR; Qian XP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):1-13. PubMed ID: 24916545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
    Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
    Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Saltz LB
    Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
    [No Abstract]   [Full Text] [Related]  

  • 37. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Matsuoka A; Maeda O; Ando Y
    N Engl J Med; 2015 Jan; 372(3):291. PubMed ID: 25587962
    [No Abstract]   [Full Text] [Related]  

  • 38. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Haines IE
    N Engl J Med; 2015 Jan; 372(3):290-1. PubMed ID: 25587961
    [No Abstract]   [Full Text] [Related]  

  • 39. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Cremolini C; Loupakis F; Falcone A
    N Engl J Med; 2015 Jan; 372(3):291-2. PubMed ID: 25587960
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.